首页> 中文期刊> 《世界肝病学杂志:英文版(电子版)》 >Apatinib as an alternative therapy for advanced hepatocellular carcinoma

Apatinib as an alternative therapy for advanced hepatocellular carcinoma

         

摘要

Angiogenesis plays an important role in the occurrence and development of tumors.Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis.Apatinib,a tyrosine kinase inhibitor,can specifically inhibit vascular endothelial growth factor receptor 2,showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma(HCC).This article intends to review the clinical research and application prospects of apatinib in the field of HCC.

著录项

  • 来源
  • 作者单位

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin 300060;

    China;

    Key Laboratory of Breast Cancer Prevention and Therapy;

    Tianjin Medical University;

    Tianjin 300060;

    China;

    Department of Breast Surgery;

    Tianjin Medical University Cancer Institute and Hospital;

    National Clinical Research Center for Cancer;

    Tianjin’s Clinical Research Center for Cancer;

    Tianjin 300060;

    China;

    Digestive Department;

    Shanxi Province Tumor Hospital;

    Taiyuan 030013;

    Shanxi Province;

    China;

    Department of Hepatobiliary Surgery;

    Tianjin Medical University Cancer Institute and Hospital;

    Tianjin 300060;

    China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    Apatinib; Hepatocellular carcinoma; Angiogenesis; Vascular endothelial growth factor receptor 2;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号